P/E ratio for Arcadia Biosciences (RKDA)
P/E ratio as of April 2024 (TTM): -0.0950
According to Arcadia Biosciences's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.0950465. At the end of 2022 the company had a P/E ratio of -0.4145.
P/E ratio history for Arcadia Biosciences from 2015 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -0.4145 | -73.73% |
| 2021 | -1.58 | -75.05% |
| 2020 | -6.32 | 400.92% |
| 2019 | -1.26 | 130.63% |
| 2018 | -0.5475 | -27.43% |
| 2017 | -0.7545 | -63.71% |
| 2016 | -2.08 | -59.49% |
| 2015 | -5.13 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Marrone Bio Innovations
MBII | N/A | N/A | 🇺🇸 USA |
 Codexis
CDXS | -3.59 | 3,675.25% | 🇺🇸 USA |
 ScottsMiracle-Gro SMG | -10.1 | 10,539.32% | 🇺🇸 USA |
 American Vanguard AVD | 29.1 | -30,742.90% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.